KR920701178A - 3-아릴옥사졸리디논 유도체, 그의 제조방법 및 그의 치료 용도 - Google Patents

3-아릴옥사졸리디논 유도체, 그의 제조방법 및 그의 치료 용도

Info

Publication number
KR920701178A
KR920701178A KR1019910700620A KR910700620A KR920701178A KR 920701178 A KR920701178 A KR 920701178A KR 1019910700620 A KR1019910700620 A KR 1019910700620A KR 910700620 A KR910700620 A KR 910700620A KR 920701178 A KR920701178 A KR 920701178A
Authority
KR
South Korea
Prior art keywords
oxygen
compound
derivatives
alkyl
formula
Prior art date
Application number
KR1019910700620A
Other languages
English (en)
Inventor
프랑스와-자비에르 쟈로
벵상조 로베
쟝-쟈끄 쾨니
알렝 쇼
Original Assignee
엘리자베드 라포르게
델라랑드 에스. 아.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엘리자베드 라포르게, 델라랑드 에스. 아. filed Critical 엘리자베드 라포르게
Publication of KR920701178A publication Critical patent/KR920701178A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms

Abstract

내용 없음

Description

3-아릴옥사졸리디논 유도체, 그의 제조방법 및 그의 치료 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (13)

  1. 부분입체 이성질체나 거울상 이성질체형 또는 시스-나 트랜스-형 또는 R1=CH3, X=산소, R2=R2'=H, n=1 또는 2 및 O=산소인 라세미체를 제외한 라세미형을 포함한 이들 모든형의 혼합물형의 다음 식(Ⅰ)의 유도체들.
    상기식에서, -R1는 수소 또는 C1-C4알킬; -X는 산소원자, 메틸렌 기 또는 -CH=CH-기; -n은 X가 산소원자 또는 메틸렌기 일때는 1또는 2, X가 -CH=CH-기 일때는 0 또는 1; -D는산소원자 또는 NOR기, 여기서, R=수소 또는 C1-C4알킬; -R3는 C1-C4알킬, C3-C7사이클로알킬, 페닐 또는 벤질기; -R2, R2' 각각은 독립적으로 수소원자 또는 C1-C4알킬, C3-C7사이클로알킬, 페닐 또는 벤질기; 및 -R2'와 R3는 또한 함께 -(CH2)3- 또는 -(CH2)4- 사슬을 형성할 수 있다.
  2. 제1항에 있어서, -R1=H 또는 CH3; -X=산소 또는 CH2; -n=1 또는 2; -R2=R2'=H 또는 CH3; -R3=C1-C4알킬; 및 -D는 산소, N-HO 또는 N-OCH3인 유도체들.
  3. 제1항에 있어서, -R1=CH3; -X=산소; -n=1 또는 2; -R2=R2'=H; -R3=CH3; 및 -D는 산소인 유도체들.
  4. 제1항에 있어서, -R1=CH3; -X=산소; -n=1 또는 2; -R2=R2'=H; -R3=CH3; 및 -D는 (E) N-OH인 유도체들.
  5. 제1항에 있어서, -R1=CH3; -X=메틸렌; -n=1 또는 2; -R2=R2'=H; -R3=CH3; 및 -D는 산소인 유도체들.
  6. 제1항에 있어서, -R1=CH3; -X=메틸렌; -n=1 또는 2; -R2=R2'=H; -R3=CH3; 및 -D는 (E) N-OH인 유도체들.
  7. 제1항에 있어서, -R1=CH3; -X는 -CH=CH-; -n=O 또는 1; -R2=R2'=H; -R3=CH3; 및 -D는 산소인 유도체들.
  8. 제1항에 있어서, -R1=CH3; -X는 -CH=CH-; -n=O 또는 1; -R2=R2'=H; -R3=CH3; 및 -D는(E) N-OH인 유도체들.
  9. 제1항에 있어서, R1=CH3; X=메틸렌; n=1; -R2=R2'=H; -R3=CH3; 및 -D는 산소인 유도체.
  10. 제3항 내지 제9항에 있어서, 비대칭 탄소원자가 (R) 구조를 갖는 유도체.
  11. 생리학적으로 허용될 수 있는 부형제와 제1항 내지 제10항 중의 어느 하나에 의한 화합물들 중에서 선택된 최소한 하나의 화합물을 포함하는 것을 특징으로 하는 제약 조성물.
  12. 의약의 제조를 위한, 제1항 내지 제10항에 의한 유도체들이 용도.
  13. a) 다음식의 화합물들을 가수분해시킴:
    (상기 식에서, R1, X, n, R2, R2' 및 R3는 식(Ⅰ)에서와 같은 의미를 갖고, R4와 R4' 각각은 독립적으로 C1-C4알킬이거나 R4와 R4'는 함께 -(CH2)2- 또는 -(CH2)3- 사슬을 형성한다) b) 다음 식의 화합물을 산화시킴
    (상기 식에서, 다른 매개변수들은 식(Ⅰ)에서와 같은 의미를 갖는다) c) C1-C4알킬 카보네이트를 다음식의 화합물과 축합반응시킴:
    (상기 식에서, n, X, R2, R2' 및 R3는 식(Ⅰ)에서와 같은 의미를 같은 의미를 갖는다)또는 d) 다음 식의 C1-C4알킬 할로게나이드 화합물과 알킬화시킴:
    (상기 식에서, n, X, R2, R2' 및 R3는 식(Ⅰ)에서와 같은 의미를 갖는다)을 특징으로 하는 제1항에 따른 식(Ⅰ)의 유도체들의 제조방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019910700620A 1989-10-17 1990-10-17 3-아릴옥사졸리디논 유도체, 그의 제조방법 및 그의 치료 용도 KR920701178A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR8913555A FR2653017B1 (fr) 1989-10-17 1989-10-17 Derives d'aryl-3 oxazolidinone-2, leur procede de preparation et leur application en therapeutique.
FR8913555 1989-10-17
PCT/FR1990/000747 WO1991005776A1 (fr) 1989-10-17 1990-10-17 Aryl-3 oxazolidinones leur preparation et utilisation

Publications (1)

Publication Number Publication Date
KR920701178A true KR920701178A (ko) 1992-08-11

Family

ID=9386480

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1019910700619A KR0149508B1 (ko) 1989-10-17 1990-10-17 3-아릴옥사졸리디논 유도체, 그의 제조 방법 및 그의 치료 용도
KR1019910700618A KR920701176A (ko) 1989-10-17 1990-10-17 3-아릴옥사졸리디논 유도체, 그의 제조 방법 및 그의 치료 용도
KR1019910700620A KR920701178A (ko) 1989-10-17 1990-10-17 3-아릴옥사졸리디논 유도체, 그의 제조방법 및 그의 치료 용도

Family Applications Before (2)

Application Number Title Priority Date Filing Date
KR1019910700619A KR0149508B1 (ko) 1989-10-17 1990-10-17 3-아릴옥사졸리디논 유도체, 그의 제조 방법 및 그의 치료 용도
KR1019910700618A KR920701176A (ko) 1989-10-17 1990-10-17 3-아릴옥사졸리디논 유도체, 그의 제조 방법 및 그의 치료 용도

Country Status (16)

Country Link
US (3) US5036090A (ko)
EP (3) EP0428421A1 (ko)
JP (3) JPH04502333A (ko)
KR (3) KR0149508B1 (ko)
AT (2) ATE126220T1 (ko)
AU (3) AU637150B2 (ko)
CA (3) CA2027783C (ko)
DE (2) DE69021823T2 (ko)
DK (1) DK0424244T3 (ko)
ES (1) ES2078958T3 (ko)
FR (1) FR2653017B1 (ko)
GR (1) GR3017708T3 (ko)
HK (1) HK1005591A1 (ko)
NZ (3) NZ235728A (ko)
WO (3) WO1991005776A1 (ko)
ZA (3) ZA908283B (ko)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5235063A (en) * 1989-10-17 1993-08-10 Delalande S.A. Process of preparing by condensation certain
US5196543A (en) * 1989-10-17 1993-03-23 Delalande S.A. 3-aryloxazolidinone derivatives, process for their preparation and their use in therapy
FR2653017B1 (fr) * 1989-10-17 1995-05-05 Delalande Sa Derives d'aryl-3 oxazolidinone-2, leur procede de preparation et leur application en therapeutique.
FR2675504B1 (fr) * 1991-04-16 1995-01-27 Delalande Sa Derives d'aryl-3 oxazolidinone, leur procede de preparation et leur application en therapeutique.
TW286317B (ko) * 1993-12-13 1996-09-21 Hoffmann La Roche
FR2715155B1 (fr) * 1994-01-19 1996-07-26 Mayoly Spindler Inhibiteurs de la monoamine oxydase B et leurs procédés de préparation.
FR2732679B1 (fr) * 1995-04-07 1997-04-30 Synthelabo Procede de preparation enzymatique d'un intermediaire de synthese de la befloxatone
FR2734820B1 (fr) * 1995-06-02 1997-07-11 Synthelabo Derives de 3-(1,2-benzisoxazol-3-yl)oxazolidin-2-one, leur preparation et leur application en therapeutique
CN1075072C (zh) * 1995-06-02 2001-11-21 圣诺菲—合成实验室公司 噁唑烷酮衍生物及其制法和用途
FR2734821B1 (fr) * 1995-06-02 1997-07-11 Synthelabo Derives de 5-methoxymethyl-3-(1,2-benzisoxazol-3-yl) oxazolidin-2-one, leur preparation et leur application en therapeutique
FR2737206B1 (fr) * 1995-07-24 1997-08-22 Synthelabo Derives d'oxazoloquinoleinone, leur preparation et leur application en therapeutique
FR2741072B1 (fr) * 1995-11-09 1997-12-12 Synthelabo Derives d'oxazolidin-2-one, leur preparation et leur application en therapeutique
FR2741071B1 (fr) * 1995-11-09 1997-12-12 Synthelabo Derives de 3-(benzofuran-5-yl)oxazolidin-2-one, leur preparation et leur application en therapeutique
US6642409B2 (en) 2000-01-27 2003-11-04 Central Glass Company, Limited Process for producing 4,4,4-trifluoro-3-hydroxybutyric acid derivatives
US6444813B2 (en) * 2000-02-02 2002-09-03 Pharmacia & Upjohn Company Linezolid-crystal form II
WO2002018354A1 (en) * 2000-08-31 2002-03-07 Abbott Laboratories Oxazolidinones and their use as antibacterial agents
EP2266590A3 (en) 2002-02-22 2011-04-20 Shire LLC Active agent delivery sytems and methods for protecting and administering active agents

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU80081A1 (fr) * 1977-08-26 1979-05-15 Delalande Sa Nouvelles hydroxymethyl-5 oxazolidinones-2,leur procede de preparation et leur application therapeutique
FR2458547B2 (fr) * 1978-06-09 1986-05-16 Delalande Sa Nouvelles n-aryle azolones, leur procede de preparation et leur application en therapeutique
FR2506769A2 (fr) * 1978-06-09 1982-12-03 Delalande Sa Para-((cyano-5 n pentyl-1) phenyl)-3 methoxymethyl-5 oxazolidinone-2, son procede de preparation et ses applications en therapeutique
US4348393A (en) * 1978-06-09 1982-09-07 Delalande S.A. N-Aryl oxazolidinones, oxazolidinethiones, pyrrolidinones, pyrrolidines and thiazolidinones
CA1171865A (en) * 1980-06-04 1984-07-31 Alain Lacour N-aryl azolone derivatives, the process for preparing the same and their application in therapeutics
FR2608604B1 (fr) * 1986-12-19 1989-04-28 Delalande Sa Derives 5-hydroxyethyles de l'oxazolidinone-2, leurs procedes de preparation et leurs applications en therapeutique
FR2653017B1 (fr) * 1989-10-17 1995-05-05 Delalande Sa Derives d'aryl-3 oxazolidinone-2, leur procede de preparation et leur application en therapeutique.

Also Published As

Publication number Publication date
EP0424243A1 (fr) 1991-04-24
JPH04502333A (ja) 1992-04-23
NZ235728A (en) 1992-04-28
AU6471490A (en) 1991-07-18
AU637150B2 (en) 1993-05-20
US5171747A (en) 1992-12-15
AU6471390A (en) 1991-06-20
FR2653017A1 (fr) 1991-04-19
JPH04502335A (ja) 1992-04-23
CA2027783A1 (en) 1991-04-18
AU635779B2 (en) 1993-04-01
NZ235729A (en) 1992-05-26
ATE126220T1 (de) 1995-08-15
KR0149508B1 (ko) 1998-10-15
WO1991005775A1 (fr) 1991-05-02
HK1005591A1 (en) 1999-01-15
FR2653017B1 (fr) 1995-05-05
WO1991005776A1 (fr) 1991-05-02
EP0424244B1 (fr) 1995-08-09
CA2027783C (en) 1996-04-30
WO1991005774A1 (fr) 1991-05-02
NZ235727A (en) 1992-04-28
CA2027782A1 (en) 1991-04-18
ATE126792T1 (de) 1995-09-15
DE69021823T2 (de) 1996-07-11
CA2027782C (en) 1996-04-30
GR3017708T3 (en) 1996-01-31
EP0424243B1 (fr) 1995-08-23
US5036091A (en) 1991-07-30
DE69021823D1 (de) 1995-09-28
ZA908284B (en) 1991-08-28
JPH04502334A (ja) 1992-04-23
AU637413B2 (en) 1993-05-27
EP0428421A1 (fr) 1991-05-22
JPH07103114B2 (ja) 1995-11-08
ES2078958T3 (es) 1996-01-01
ZA908283B (en) 1991-08-28
DE69021498T2 (de) 1996-03-28
ZA908285B (en) 1991-08-28
AU6471590A (en) 1991-06-20
KR920701176A (ko) 1992-08-11
KR920701177A (ko) 1992-08-11
US5036090A (en) 1991-07-30
EP0424244A1 (fr) 1991-04-24
DK0424244T3 (da) 1996-01-02
DE69021498D1 (de) 1995-09-14
CA2027715A1 (en) 1991-04-18

Similar Documents

Publication Publication Date Title
KR920701178A (ko) 3-아릴옥사졸리디논 유도체, 그의 제조방법 및 그의 치료 용도
HUP9600448A2 (hu) Naftilvegyületek, e vegyületeket tartalmazó gyógyszerkészítmények, eljárás előállításukra, intermedierjeik és alkalmazásuk
DK142084D0 (da) N-phenyl-n'-cycloalkylalkanoyl-piperaziner og fremgangsmaade til fremstilling heraf
ATE19878T1 (de) Benzimidazol-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
ES2051834T3 (es) El uso de tetrahidrobenzeno(c,d)indol-6 carboxamidas para la preparacion de un medicamento para el tratamiento de la ansiedad.
IT1317048B1 (it) Uso dell'acido pamoico o di un suo derivato, o di un suo analogo, perla preparazione di un medicamento per il trattamento di patologie
NO161620C (no) Analogifremgangsm te for fremstilling av terapeutisk aktive 8-alkyltio-2-piperazino-pyrimido(5,4-d)pyrimidin-derivater.
KR880007462A (ko) 빈뇨치료용 프로피오페논 유도체
KR950032191A (ko) 사이클로헥산 유도체, 이의 제조방법 및 질병을 치료하기 위한 화합물의 용도
ATE28871T1 (de) Disubstituierte piperidine,verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
KR950704322A (ko) 스피로푸라논 유도체 및 그의 신경변성 질환 치료 용도(Spirofuranone Derivatives and Their Use in the Treatment of Neurodegenerative Disorders)
DK460789D0 (da) 2-aminoacetamidderivater
DE69111311D1 (de) 2-Tetrahydrofuran-Enantiomerderivate, Zwischenprodukte davon und ihre Herstellung.
EP0351696A3 (de) Allylaminoethylazole
ES440767A2 (es) Procedimiento para la preparacion de derivados de fenileti- lamina.
TH2508EX (th) 9-อะมิโนแอลคิลฟลูออรีน
TH2508A (th) 9-อะมิโนแอลคิลฟลูออรีน
TH1819B (th) การเตรียมอนุพันธ์ 1-แอลคิล-2-อะมิโน-เททราลิน

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid